Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS

Show simple item record

dc.contributor.author Favero, Francis Meire [UNIFESP]
dc.contributor.author Voos, Mariana Callil
dc.contributor.author de Castro, Isac
dc.contributor.author Caromano, Fatima Aparecida
dc.contributor.author Bulle Oliveira, Acary Souza [UNIFESP]
dc.date.accessioned 2019-08-19T11:49:58Z
dc.date.available 2019-08-19T11:49:58Z
dc.date.issued 2017
dc.identifier http://dx.doi.org/10.1590/0004-282X20170083
dc.identifier.citation Arquivos De Neuro-Psiquiatria. Sao Paulo Sp, v. 75, n. 8, p. 515-522, 2017.
dc.identifier.issn 0004-282X
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/51446
dc.description.abstract Objective: To investigate the impact of epidemiological and clinical factors on the benefit of riluzole in patients with amyotrophic lateral sclerosis (ALS). Methods: The survival rate of 578 patients with ALS (1999-2011) was analyzed by descriptive statistics and Kaplan-Meier curves. Considering the median of the sample survival time (19 months), patients were divided in two groups: below (B19) and above the median (A19). Kaplan-Meier curves compared the survival rates of patients treated with riluzole and with patients who did not take the medication. Results: Riluzole increased the survival rates of patients with lower limb onset who were diagnosed after the first appointment in B19. Patients with bulbar onset and diagnosed on the first, or after the first appointment showed higher survival rates in A19. Males lived longer than females in both groups. Conclusion: Epidemiological and clinical factors influenced the benefit of riluzole in the survival rates of patients with ALS. en
dc.description.abstract Objetivo Investigar o impacto de fatores epidemiológicos e clínicos sobre o benefício do riluzole em pacientes com esclerose lateral amiotrófica (ELA). Métodos A sobrevida de 578 pacientes com ELA (1999-2011) foi analisada por estatística descritiva e curvas de Kaplan-Meier. Considerando a mediana do tempo de sobrevida (19 meses), a amostra foi subdividida em dois grupos: sobrevida abaixo (B19) e acima de 19 meses (A19). As curvas de Kaplan-Meier compararam a sobrevida de pacientes tratados com riluzole e com pacientes que não receberam tratamento. Resultados O riluzole aumentou a sobrevida de pacientes com início nos membros inferiores e diagnosticados após a primeira consulta no grupo B19. Pacientes com início bulbar e diagnosticados na primeira/ após a primeira consulta apresentaram maior sobrevida em A19. Os homens apresentaram sobrevida maior do que as mulheres. Conclusão Foram encontradas diferenças epidemiológicas e clínicas no benefício do riluzole em pacientes com ELA. pt
dc.format.extent 515-522
dc.language.iso eng
dc.publisher Assoc Arquivos Neuro- Psiquiatria
dc.rights Acesso aberto
dc.subject epidemiology en
dc.subject amyotrophic lateral sclerosis en
dc.subject motor neuron disease en
dc.subject survival en
dc.subject riluzole en
dc.subject epidemiologia pt
dc.subject esclerose amiotrófica lateral pt
dc.subject doença dos neurônios motores pt
dc.subject sobrevivência pt
dc.subject riluzole pt
dc.title Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS en
dc.title.alternative Impacto de fatores epidemiológicos e clínicos sobre o benefício do riluzol nas taxas de sobrevida de pacientes com ELA pt
dc.type Artigo
dc.description.affiliation Univ Fed São Paulo, Dept Neurol & Neurocirurgia, São Paulo, SP, Brazil
dc.description.affiliation Univ São Paulo, Fac Med, Dept Fisioterapia Fonoaudiol & Terapia Ocupac, São Paulo, SP, Brazil
dc.description.affiliation Univ São Paulo, Fac Med, Dept Nefrol, São Paulo, SP, Brazil
dc.description.affiliationUnifesp Univ Fed São Paulo, Dept Neurol & Neurocirurgia, São Paulo, SP, Brazil
dc.identifier.file WOS000407795800006.pdf
dc.identifier.scielo S0004-282X2017000800515
dc.identifier.doi 10.1590/0004-282X20170083
dc.description.source Web of Science
dc.identifier.wos WOS:000407795800006



File

Name: WOS000407795800006.pdf
Size: 682.5Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account